Myeloma Posts
Multiple myeloma updates with Dr. Lonial
In a video interview during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California, Sagar Lonial, MD, FACP, discusses multiple myeloma updates from the […]
Refining progression criteria in relapsed myeloma
Jean-Sébastien Claveau, MD, of Maisonneuve-Rosemont Hospital at the University of Montreal, spoke with SOHO Insider at the 66th American Society of Hematology Annual Meeting and Exposition in San Diego, California, […]
Researchers call for ‘evidence-based’ driving restrictions for patients treated with CAR-T therapy
Driving restrictions for blood cancer patients undergoing chimeric antigen receptor (CAR)-T cell therapy may need reconsideration.
Daratumumab monotherapy superior to active monitoring in high-risk smoldering myeloma
Daratumumab demonstrated a clinically meaningful and significant benefit compared with active monitoring, the current standard of care, for patients with high-risk smoldering multiple myeloma (SMM), according to results from the […]
Triplet regimen shows promise in relapsed or refractory multiple myeloma
Elranatamab in combination with carfilzomib and dexamethasone demonstrated clinical efficacy and predictable safety signals, according to the investigators of a phase 1b MagnetisMM-20 trial in relapsed or refractory multiple myeloma. […]
